U.S. markets closed

Zelira Therapeutics Limited (ZLDAF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0355+0.0008 (+2.16%)
At close: 3:19PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0347
Open0.0356
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0350 - 0.0356
52 Week Range0.0315 - 0.0900
Volume132,834
Avg. Volume87,258
Market Cap42.27M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation
      Simply Wall St.

      A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

      Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...

    • Zelira Therapeutics Expands HOPE™ Distribution in the US Through Licensing Agreement with Alternative Solutions in Washington DC
      PR Newswire

      Zelira Therapeutics Expands HOPE™ Distribution in the US Through Licensing Agreement with Alternative Solutions in Washington DC

      Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.

    • Zelira Therapeutics Enters Agreement with Cardiovascular Solutions of Central Mississippi to Develop Products
      PR Newswire

      Zelira Therapeutics Enters Agreement with Cardiovascular Solutions of Central Mississippi to Develop Products

      Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding agreement with US-based Cardiovascular Solutions of Central Mississippi to develop products that target symptoms and health risks related to cardiovascular disease and diabetes. According to the Agreement, Zelira will develop exclusively for CVSCM novel, hemp-derived formulations of CBD and other cannabinoids to address a range of therapeutic needs associated with Peripheral Arterial Disease (PAD) and Diabetic Neuropathies (DPN).